ARK

Ark Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative drugs for viral infections and fibrosis. The company's lead program, ziresovir (AK0529), is a first-in-class small molecule inhibitor of the respiratory syncytial virus (RSV) fusion protein, which has successfully completed a pivotal Phase 3 clinical trial in pediatric patients. Ark Biosciences is also advancing a pipeline of candidates for other unmet needs, including idiopathic pulmonary fibrosis (IPF) and chronic hepatitis B. Headquartered in Shanghai with R&D facilities in Suzhou, the company leverages its internal research capabilities and global partnerships to address significant public health challenges.